ABBOTT LABORATORIES
For the period ended Dec 31, 2024. Filed Feb 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 21, 2025
ABT$110.51+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Cash Flows
| Year Ended December 31 | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $13,402 | $5,723 | $6,933 |
| Adjustments to reconcile earnings to net cash from operating activities — | |||
| Depreciation | 1,340 | 1,277 | 1,254 |
| Amortization of intangible assets | 1,878 | 1,966 | 2,013 |
| Share-based compensation | 673 | 644 | 685 |
| Investing and financing losses, net | 482 | 126 | 215 |
| Trade receivables | (691) | (356) | (68) |
| Inventories | (58) | (232) | (1,413) |
| Prepaid expenses and other assets | (796) | (542) | (75) |
| Trade accounts payable and other liabilities | 356 | (760) | 420 |
| Income taxes | (8,028) | (585) | (383) |
| Net Cash From Operating Activities | 8,558 | 7,261 | 9,581 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of property and equipment | (2,207) | (2,202) | (1,777) |
| Acquisitions of businesses and technologies, net of cash acquired | — | (877) | — |
| Proceeds from business dispositions | 1 | 40 | 48 |
| Purchases of investment securities | (169) | (159) | (185) |
| Proceeds from sales of investment securities | 28 | 43 | 152 |
| Other | 9 | 22 | 22 |
| Net Cash From (Used in) Investing Activities | (2,338) | (3,133) | (1,740) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt, net and other | (100) | 21 | 47 |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 223 | 2 | 7 |
| Repayments of long-term debt and debt with maturities over 3 months | (660) | (2,498) | (753) |
| Purchases of common shares | (1,295) | (1,227) | (3,795) |
| Proceeds from stock options exercised | 264 | 167 | 167 |
| Dividends paid | (3,836) | (3,556) | (3,309) |
| Net Cash From (Used in) Financing Activities | (5,404) | (7,091) | (7,636) |
| Effect of exchange rate changes on cash and cash equivalents | (96) | (23) | (122) |
| Net Increase (Decrease) in Cash and Cash Equivalents | 720 | (2,986) | 83 |
| Cash and Cash Equivalents, Beginning of Year | 6,896 | 9,882 | 9,799 |
| Cash and Cash Equivalents, End of Year | $7,616 | $6,896 | $9,882 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | $1,723 | $1,475 | $1,864 |
| Interest paid | 604 | 662 | 563 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.